Gene Map of Gut-Dwelling Yeast Points Toward More Precise Drug Delivery Timing
The human gut is home to trillions of microbes that collectively influence digestion, immunity, and increasingly, the delivery of therapeutic compounds. Among the most promising tools in this space is Saccharomyces boulardii, a yeast already approved as an over-the-counter probiotic. Unlike most gut microbes, it is well-tolerated, non-pathogenic, and capable of being genetically modified to produce specific therapeutic molecules on demand inside the intestine.
The challenge is engineering it well. Previous work demonstrated that modified yeast can produce anti-inflammatory compounds and other drugs at the site where they are needed. But nobody had systematically mapped what S. boulardii does at the molecular level when it enters the gut - which genes switch on, what the yeast eats, whether it produces anything potentially dangerous. Without that information, engineering is essentially guesswork.
A research team at North Carolina State University, led by associate professor Nathan Crook in the Department of Chemical and Biomolecular Engineering, set out to fill that gap. Their findings, published open access in BMC Genomics, provide what Crook describes as "a roadmap for the most promising paths forward."
The Germ-Free Mouse Approach
In a normal gut, thousands of microbial species express genes simultaneously. Isolating RNA specifically from S. boulardii cells amid that noise is technically difficult. The team solved it by using germ-free mice - animals raised in sterile conditions with no gut microbiome. When S. boulardii was introduced into these mice, any RNA detected in fecal and intestinal samples came from the yeast alone. The team used an unmodified, commercially available strain to establish a baseline measurement of natural gut behavior. Co-lead authors Genan Wang, a postdoctoral researcher, and Deniz Durmusoglu, a former PhD student, led the experimental work.
Which Genes Light Up in the Gut
The central finding is identification of genes in S. boulardii that are substantially more active in the gut than in standard laboratory conditions. These genes occupy "promoter" regions - DNA stretches that act as on-switches. For drug delivery, these gut-responsive promoters are exactly what engineers need. Linking therapeutic protein production to a promoter that activates specifically under intestinal conditions ensures precise timing and location. "We've identified the best candidates for helping us ensure the yeast cell is producing medicine when we want it to, which makes it a much more efficient drug-delivery platform," Crook explained.
Safety and Nutrition Findings
The team also verified that gut conditions did not activate genes associated with pathogenic behavior - consistent with S. boulardii's safety record as a probiotic, but important to confirm at the gene expression level before engineering begins. Gene expression patterns also indicated that the gut provides relatively little in the way of carbohydrates; cells were preferentially digesting lipids. This matters because yeast cells producing therapeutic molecules need metabolic energy to do so efficiently. Modifying the yeast to better utilize complex gut carbohydrates may be a worthwhile next engineering target.
The authors have filed patent applications related to probiotic yeast engineering. The work was supported by NSF (grant 1934284), the Novo Nordisk Foundation (grant NNF19SA0035474), and NIH (grant 1DP2AT012795-01).